Zimmer Biomet (NYSE:ZBH) Rating Lowered to Hold at Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Other equities research analysts have also recently issued research reports about the stock. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research report on Thursday, September 18th. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research report on Wednesday, November 5th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Raymond James Financial raised their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Trading Down 1.3%

Shares of NYSE ZBH opened at $88.72 on Friday. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.72. The business has a fifty day moving average price of $98.24 and a 200 day moving average price of $96.93. The stock has a market capitalization of $17.58 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Institutional Trading of Zimmer Biomet

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Key Financial Inc lifted its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. increased its holdings in shares of Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC purchased a new stake in Zimmer Biomet during the third quarter worth $31,000. Finally, Accent Capital Management LLC purchased a new stake in Zimmer Biomet during the first quarter worth $35,000. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.